Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and SBRT in metastatic urothelial cancer
NCT02826564Phase 1Completed
- Sponsor
- Ghent University Hospital
- Start
- Nov 2016
- Primary completion
- Apr 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pembrolizumab in urothelial carcinoma (UC), sponsored by Ghent University Hospital. Started Nov 2016; status: completed.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02826564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02826564.